References

  • Patel S. Primary bone marrow oedema syndromes. Rheumatology. 2014;53:785–792.
  • Singh D, Ferrero A, Rose B, Goldberg A, Cullen N. Bone marrow edema syndrome of the foot and ankle: mid-to long-term follow-up in 18 patients. Foot Ankle Spec. 2015;12:1–9.
  • Simon MJ, Bervencik J, Luttke M, Amling M, Mueller-Wohlfahrt HW, Ueblacker P. Intravenous bisphosponates and Vitamin D in the treatment of bone marrow oedema in professional athletes. Injury. 2014;45:981–987.
  • Starr AM, Wessely MA, Albastaki U, Pierre-Jerome C, Kettner NW. Bone marrow oedema: pathophysiology, differential diagnosis, and imaging. Acta Radiol. 2008;49:771–786.
  • Meizer R, Radda C, Stolz G, et al. MRI-controlled analysis of 104 patients with painful bone marrow edema in different joint localizations treated with prostacyclin analogue iloprost. Wien Klin Wochenschr. 2005;117:278–286.
  • Aigner N, Petje G, Steinboeck G, Schneider W, Krasny C, Landsiedl F. Treatment of bone marrow oedema of the talus with the prostacyclin analogue iloprost. J Bone Surg Br. 2001;83:855–858.
  • Baier C, Scahumburge J, Götz J, et al. Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot. Rheumatol Int. 2013;33:1397–1402.
  • Cavallasca JA, Borgia AR, Sohn Dl, et al. Boné marrow edema syndrome of the hip: analysis of 10 cases. Int J Rheum Dis. 2014;17:580–582.
  • Ringe JD, Dorst A, Faber H. Effective and rapid treatment on painful localized transient osteoporosis (bone marrow oedema) with intravenous ibandronate. Osteoporos Int. 2005;16(12):2063–2068.
  • Varenna M, Zucchi F, Binelli L, Failoni S, Gallazzi M, Sinigaglia L. Intravenous pamidronate in the treatment of transient osteoporosis of the hip. Bone. 2002;31(1):96–101.
  • Carty S, Herdman G, Williams F, Srinivasan U. Transient migratory osteoporosis: rapid response to pamidronate treatment. J Clin Rheumatol. 2007;13:138–139.
  • Kibbi L, Touma Z, Khouty N, Arayssi T. Oral bisphosphonates in treatment of transient osteoporosis of the hip. Clin Rheumatol. 2008;27:529–532.
  • Emad Y, Ragab Y, El-Shaarway N, Rasker JJ. Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI: description of eight cases and review of the literature. Clin Rheumatol. 2012;31:1641–1647.
  • Schapira D, Moscovici YB, Gutiérrez G. Severe transient osteoporosis of the hip during pregnancy: successful treatment with intravenous bisphosphonates. Clin Exp Rheumatol. 2003;12:107–110.
  • Ringe JD, Body JJ. A review of bone pain relief with ibandronate and other bisphosphonates in disorders of increased bone turnover. Clin Exp Rheumatol. 2007;25:766–774.
  • Berger CE, Kroner AH, Minai-Pour MB, Ogris E, Engel A. Biochemical markers of bone metabolism in bone marrow oedema syndrome of the hip. Bone. 2003;33:346–351.
  • Varenna M. Bisphosphonates beyond their anti-osteoclastic properties. Rheumatology. 2014;53:965–967.
  • Assouline-dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32:94–124.
  • Varenna M, Adami S, Rossini M, et al. Treatment of complex regional pain syndrome type I with neridronate: a randomized double-blind, placebo-controlled study. Rheumatology. 2013;52:534–542.
  • Disch AC, Matziolis G, Perka C. The management of necrosis-associated and idiopathic bone marrow oedema of the proximal femur by intravenous iloprost. J bone Joint Surg Br. 2005;87:560–564.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.